Compare prices and buy PEG-MGF from 8 research peptide vendors - also called suppliers or sources. Updated daily.
A polyethylene glycol-conjugated form of the MGF E-domain peptide, marketed on the rationale that pegylation increases its stability and prolongs exposure. The muscle and cardiac findings usually cited for it come from studies of native MGF and its synthetic E-domain peptide, and no half-life has been reported for the conjugate itself. No published human studies and not FDA-approved.
For research purposes only. Not medical advice.
Mechano growth factor, or MGF, is the name given to a splice variant of the IGF-1 gene whose expression responds to mechanical stress in skeletal muscle. In human nomenclature the variant is IGF-1Ec, while rodent papers call the corresponding transcript IGF-1Eb, a naming split that a 2012 review in Frontiers in Endocrinology (Zablocka and colleagues) traces to splicing that produces slightly different reading frames in the two species.
What vendors sell is not the whole isoform. It is a synthetic peptide matching the 24 C-terminal residues of the variant's E domain. The variant's mature IGF-1 region is identical to that of other IGF-1 forms, so the E domain is where MGF differs. FDA's Global Substance Registration System registers mechano growth factor as that 24-residue sequence under UNII Q86M4KXC2P. A 2010 minireview in Endocrinology (Matheny, Nindl and Adamo) added a caveat: no matching peptide product of the IGF-1 gene had been identified in or isolated from cells, animal tissues or body fluids.
PEG-MGF is that peptide with polyethylene glycol attached. Two details are not published. None of the vendor pages we could read in October 2026 states where the polyethylene glycol attaches or how large it is, and we found no paper that characterizes the conjugate.
Vendors market PEG-MGF on the rationale that pegylation increases stability and prolongs exposure, a rationale the 2026 review by Dominikowski and colleagues in Frontiers in Endocrinology describes as commercially promoted. The case for stabilizing the peptide at all comes from the MGF literature itself: the 2012 review notes that synthetic E-domain peptides benefit from chemical stabilization and that their endogenous equivalents are predicted to have a very short half-life.
No half-life has been reported for the conjugate. The 2026 review's summary table lists PEG-MGF's half-life as not reported, and PubMed searches for "PEG-MGF" and "pegylated mechano growth factor" on October 21, 2026 returned no pharmacokinetic study of it. The same review cautions that pegylation alters pharmacokinetics and tissue exposure, so effects seen with native IGF-1Ec or the isolated E-domain peptide cannot be assumed to apply to a PEG conjugate.
Two studies the 2026 review cites show what that research covers:
Neither abstract describes a pegylated peptide. The 2026 review places PEG-MGF in its lowest evidence tier, with no peer-reviewed human studies, and ClinicalTrials.gov returns no registered study of PEG-MGF as of October 2026.
FDA placed PEG-MGF, listed as mechano growth factor pegylated, in Category 2 of its Section 503A interim policy on September 29, 2023. The entry cites a significant risk of immunogenicity for certain routes of administration, complexities with peptide-related impurities and characterization of the active ingredient, and no human exposure data on any route.
In April 2026 FDA moved it to that page's table of nominations withdrawn by their nominators, with the safety text unchanged, and the May 2026 update of the 503A nominations list no longer places it in any category. The category overview covers the wider April 2026 removals. Leaving Category 2 did not put PEG-MGF on the 503A bulks list.
FDA's advisory committee page lists Mechano Growth Factor, Pegylated (PEG-MGF) among five substances the Pharmacy Compounding Advisory Committee will discuss for possible inclusion on the 503A bulks list at a meeting before the end of February 2027, alongside LL-37, GHK-Cu, dihexa and melanotan II. As of October 21, 2026 the page gives no date and says the time and location will be scheduled in the coming months. Our February 2027 slate post previews that meeting.
The unpegylated peptide is a separate nomination. The same May 2026 list places mechano growth factor (MGF) in Category 3, substances nominated without adequate support.
Vendors title the product PEG-MGF or PEG MGF, and one vendor's copy spells it out as pegylated mechano growth factor. PeptideScouter indexes it as its own row, separate from unpegylated MGF, because the two are different substances and FDA's nomination names the pegylated form. The listings indexed here are vials, sold singly or as a 10-vial kit, so each carries a per-milligram price.
MGF, or mechano growth factor, is sold as a synthetic peptide matching the 24 C-terminal residues of the E domain of IGF-1Ec, a splice variant of the IGF-1 gene. PEG-MGF is the same peptide with polyethylene glycol attached, a modification marketed to increase stability and prolong exposure. The vendor pages and published papers checked in October 2026 do not state where the polyethylene glycol attaches or how large it is, and no half-life has been reported for the conjugate. FDA handles them as separate substances, and its compounding nomination names the pegylated form specifically.
No published human study was found. A 2026 review in Frontiers in Endocrinology placed PEG-MGF in its lowest evidence tier, with no peer-reviewed human studies, ClinicalTrials.gov lists no registered study of PEG-MGF as of October 2026, and FDA's Category 2 entry states that the agency identified no human exposure data by any route. The muscle and cardiac findings cited for it come from cell and animal studies of the unpegylated MGF E-domain peptide.
FDA placed PEG-MGF in Category 2 of its Section 503A interim policy, substances that may present significant safety risks, on September 29, 2023, citing immunogenicity risk, impurity and characterization complexities and no human exposure data. In April 2026 FDA moved it to its table of nominations withdrawn by their nominators, and it is not on the 503A bulks list. FDA has said its Pharmacy Compounding Advisory Committee will consider PEG-MGF for that list at a meeting before the end of February 2027, and as of October 21, 2026 no date had been set.
Yes, as a class. The World Anti-Doping Agency's 2027 Prohibited List, which takes effect on January 1, 2027, names mechano growth factors (MGFs) in section S2.3, growth factors and growth factor modulators, and everything in section S2 is prohibited at all times, in and out of competition. The list names MGFs as a class and does not name PEG-MGF separately.
PEG-MGF is sold by 8 research peptide vendors indexed on PeptideScouter, with 9 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
5 of the 8 indexed vendors currently have PEG-MGF in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Peptide Titans currently lists PEG-MGF at $17.50/mg, the lowest listed price across 8 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $15.04/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 8 vendors listing PEG-MGF publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $17.50/mg listed to $15.04/mg at Iron Protocol. Each vendor's code is shown beside its price in the table above.
PEG-MGF ranges from $17.50/mg to $23.98/mg across 9 listings from 8 research peptide vendors, normalized to USD per milligram and refreshed daily.
8 research peptide vendors currently list PEG-MGF on PeptideScouter, with 5 in stock right now. We track 9 listings across size and kit variants.
PEG-MGF's CAS Registry Number is 108174-48-7.
